PUBLICATION
Light-Triggered Cancer Cell Specific Targeting and Liposomal Drug Delivery in a Zebrafish Xenograft Model
- Authors
- Kong, L., Chen, Q., Campbell, F., Snaar-Jagalska, E., Kros, A.
- ID
- ZDB-PUB-200214-11
- Date
- 2020
- Source
- Advanced Healthcare Materials 9(6): e1901489 (Journal)
- Registered Authors
- Keywords
- cancer nanomedicine, embryonic zebrafish, in vivo, light activation, liposomes
- MeSH Terms
-
- Animals
- Cell Line, Tumor
- Doxorubicin
- Drug Delivery Systems
- Heterografts
- Humans
- Liposomes*
- Nanomedicine
- Neoplasms*
- Zebrafish
- PubMed
- 32052583 Full text @ Adv. Healthc. Mater.
Citation
Kong, L., Chen, Q., Campbell, F., Snaar-Jagalska, E., Kros, A. (2020) Light-Triggered Cancer Cell Specific Targeting and Liposomal Drug Delivery in a Zebrafish Xenograft Model. Advanced Healthcare Materials. 9(6):e1901489.
Abstract
Cell-specific drug delivery remains a major unmet challenge for cancer nanomedicines. Here, light-triggered, cell-specific delivery of liposome-encapsulated doxorubicin to xenograft human cancer cells in live zebrafish embryos is demonstrated. This method relies on light-triggered dePEGylation of liposome surfaces to reveal underlying targeting functionality. To demonstrate general applicability of this method, light-triggered, MDA-MB-231 breast cancer cell specific targeting in vivo (embryonic zebrafish) is shown using both clinically relevant, folate-liposomes, as well as an experimental liposome-cell fusion system. In the case of liposome-cell fusion, the delivery of liposomal doxorubicin direct to the cytosol of target cancer cells results in enhanced cytotoxicity, compared to doxorubicin delivery via either folate-liposomes or free doxorubicin, as well as a significant reduction in xenograft cancer cell burden within the embryonic fish.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping